2023.11.06
I-Mab Announces Participation at Jefferies and Piper Conferences in November
The Company will have presentations and one-to-one meetings during the upcoming two investor conferences.
2023.11.02
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
CD38 antibody felzartamab has been granted Breakthrough Therapy Designation by the U.S. FDA, following the Orphan Drug Designation received in May 2023.
2023.11.01
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
The Company will report preclinical data of givastomig and TJ-L14B, respectively, at the upcoming SITC 2023.
2023.10.16
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
The Company will present updated clinical data of givastomig at the upcoming ESMO Congress 2023.
2023.10.10
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
The Company announced multiple recent developments for TJ-L14B.
2023.09.05
I-Mab Announces Upcoming Participation at September Conferences
I-Mab announced participation in investor conferences in September 2023.
2023.08.17
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
The Company today announced its financial results for the 6 months ended June 30, 2023, and provided key business updates.
2023.08.08
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
I-Mab will host an investor call to report interim earnings on Aug 17.
2023.07.05
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
The Company published a manuscript in JITC demonstrating mechanism of givastomig in the treatment of CLDN18.2-expressing tumors through the targeted activation of 4-1BB mediated T cells.
2023.06.22
I-Mab Announces the Appointment of Raj Kannan as CEO
Mr. Raj Kannan joins the Company as Chief Executive Officer and a member of the board of directors.